Tanese, Keiji

写真a

Affiliation

School of Medicine, Department of Dermatology （Shinanomachi）

Position

Senior Assistant Professor (Non-tenured)/Assistant Professor (Non-tenured)
Page Top ▲

Academic Background 【 Display / hide 】

  • 1995.04
    -
    2001.03

    Keio University, School of Medicine

    University, Graduated

  • 2003.04
    -
    2007.03

    Keio University, School of Medicine, Department of Dermatology Post graduate School

    Graduate School, Graduated, Doctoral course

Page Top ▲

Academic Degrees 【 Display / hide 】

  • 医学博士, 慶應義塾大学, Coursework, 2009.02

    13. Tanese K, Fukuma M, Yamada T, Mori T, Yoshikawa T, Watanabe W, Ishiko A, Amagai M, Nishikawa T, Sakamoto M. G-protein-coupled receptor GPR49 is up-regulated in basal cell carcinoma and promotes cell proliferation and tumor formation. The American journal of pathology. 2008;173(3):835-43.

Page Top ▲

Licenses and Qualifications 【 Display / hide 】

  • 医師免許, 2001.05

  • 日本皮膚科学会皮膚科専門医, 2008.10

Page Top ▲
 

Research Areas 【 Display / hide 】

  • Dermatology

Page Top ▲

Research Keywords 【 Display / hide 】

  • Dermatopathology

  • Oncology

  • Tumor Pathology

  • Drug regulation

Page Top ▲

Research Themes 【 Display / hide 】

  • Analysis of Tumor microenvironment in melanoma, 

    2013
    -
    Present

Page Top ▲
 

Papers 【 Display / hide 】

  • Metastatic Cutaneous Squamous Cell Carcinoma in Liver Successfully Treated With Partial Hepatectomy and Adjuvant Irinotecan Chemotherapy

    Asahina Y, Nakamura Y, Tanese K, Hirai I, Fukuda K, Amagai M, Funakoshi T

    In Vivo 34 （ 2 ） 825 - 828 2020.03

    Joint Work, Accepted,  ISSN  0258-851X

  • Case of metastatic cutaneous myoepithelial carcinoma lacking severe cytological atypia

    Hirai I, Tanese K, Nakamura Y, Amagai M, Mikami S, Funakoshi T

    J Dermatol 47 （ 3 ） e97 - e98 2020.03

    Joint Work, Accepted,  ISSN  0385-2407

  • Serum cytokeratin 19 fragment 21-1 and carcinoembryonic antigen combination assay as a biomarker of tumour progression and treatment response in extramammary Paget's disease

    Nakamura Y, Tanese K, Hirai I, Amagai M, Kawakami Y, Funakoshi T

    Br J Dermatol （British Journal of Dermatology)  181 （ 3 ） 535 - 543 2019.09

    Joint Work, Accepted,  ISSN  0007-0963

    　View Summary

    © 2019 British Association of Dermatologists Background: Extramammary Paget disease (EMPD) is a rare intraepithelial adenocarcinoma affecting the genitals and axillary regions. As metastasis of these tumours is itself rare, solid disease management strategies have not been established. Serum carcinoembryonic antigen (CEA) and cytokeratin 19 fragment 21-1 (CYFRA 21-1) levels have been identified as candidate biomarkers for tumour progression in EMPD. Objectives: To determine the accuracy of and the correlation between these markers in patients with EMPD. Methods: Serum CEA and CYFRA 21-1 levels were examined in 30 patients with EMPD treated at Keio University Hospital, and compared against clinical information. Both assays were performed at the time of diagnosis, during the postoperative observation period, and following systemic treatment in those with confirmed metastasis. Serum levels were then correlated with tumour progression status and treatment responses. Results: Normal levels for both assays were observed in all 11 patients with primary localized disease (100%). In patients with metastatic disease the CEA positivity rate was 79% (15 of 19 patients), with a rate of 63% (12 of 19 patients) for CYFRA 21-1. Changes in CEA and CYFRA 21-1 levels were statistically independent; however, using a combined view, elevated levels of either marker improved the positivity rate to 95% (18 of 19 patients). Use of both markers also correlated well with treatment responses. Conclusions: The combination of CEA and CYFRA 21-1 is useful for predicting metastasis and treatment response in patients with EMPD, especially in those who only have elevation of a single marker. What's already known about this topic?. Serum levels of carcinoembryonic antigen (CEA) and cytokine 19 fragment 21-1 (CYFRA 21-1) have been shown to be elevated in patients with extramammary Paget disease (EMPD). Elevation of serum CEA levels is associated with tumour progression of EMPD. A single small study reported that serum CYFRA 21-1 levels are elevated in patients with EMPD with lymph node metastasis. What does this study add?. Serum CEA and CYFRA 21-1 were present in 79% and 63% of 19 cases of metastatic EMPD, respectively. Elevations of CEA and CYFRA 21-1 were statistically independent. CEA and CYFRA 21-1 combination assays were positive in 95% of cases of metastatic EMPD. What is the translational message?. Combination assays with CEA and CYFRA 21-1 are useful for monitoring treatment response in patients with metastatic EMPD, particularly in those with elevation of either marker.

  • Successful control of adrenal metastasis with transcatheter arterial chemoembolization in metastatic melanoma patient undergoing treatment with immune checkpoint inhibitor

    Tahara U, Tanese K, Nakamura Y, Hirai I, Amagai M, Oguro S, Funakoshi T

    J Dermatol 46 （ 8 ） e276 - e278 2019.08

    Joint Work, Accepted,  ISSN  0385-2407

  • Basosquamous cell carcinoma arising from an infundibular cyst on the hip

    Shiina Y, Ogata D, Tanese K, Arai E, Tsuchida T

    J Dermatol 46 （ 8 ） e283 - e284 2019.08

    Joint Work, Accepted,  ISSN  0385-2407

display all >>

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

display all >>

Page Top ▲

Presentations 【 Display / hide 】

  • 高齢女性の左前胸部に生じたMammary-type myofibroblastomaの1例

    早川道太郎, 八代聖, 中村善雄, 種瀬啓士, 天谷雅行, 亀山香織, 山上淳

    第887回日本皮膚科学会東京地方会（城西地区） (東京) , 2019.12

  • エキシマライトによる紫外線療法が著効した汎発型限局性強皮症の1例

    土屋茉里絵, 八代聖, 新川宏樹, 村上香織, 大内健嗣, 種瀬啓士, 天谷雅行, 谷川瑛子

    第83回日本皮膚科学会東京・東部支部合同学術大会 (東京) , 2019.11

  • Combination assay of serum cytokertatin 19 fragment 21-1 and carcinoembryonic antigen as a biomarker of tumor progression and treatment response in extramammary Paget's disease

    Nakamura Y, Tanese K, Hirai I, Kawakami Y, Amagai M, Funakoshi T

    28th European Academy of Dermatology and Venereology congress（EADV2019） (Madrid, Spain) , 2019.10

  • AMED治験・臨床研究推進事業の一環としての患者登録型マッチングシステムの構築

    舩越建, 石井麻貴, 平井郁子, 中村善雄, 種瀬啓士, 天谷雅行

    第70回日本皮膚科学会中部支部学術大会 (金沢) , 2019.10

  • The MIF-CD74 interaction regulates the expression of PD-L1 in melanoma cells

    Tanese K, Imaoka M, Masugi Y, Hayashi M, Sakamoto M

    78th Annual Meeting of the Japanese Cancer Association (Kyoto, Japan) , 2019.09

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • Analysis of the clinical influence of Hegehog signaling activation in melanoma.

    2020.04
    -
    2023.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, 種瀬 啓士, Grant-in-Aid for Scientific Research (C), Principal Investigator

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • LECTURE SERIES, DERMATOLOGY

    2021

  • LECTURE SERIES, DERMATOLOGY

    2020

Page Top ▲